CL2012001950A1 - Uso de una cepa bacteriana probiotico en la fabricacion de un medicamento o composicion nutricional en humanos o animales para alterar los patrones del sueño - Google Patents

Uso de una cepa bacteriana probiotico en la fabricacion de un medicamento o composicion nutricional en humanos o animales para alterar los patrones del sueño

Info

Publication number
CL2012001950A1
CL2012001950A1 CL2012001950A CL2012001950A CL2012001950A1 CL 2012001950 A1 CL2012001950 A1 CL 2012001950A1 CL 2012001950 A CL2012001950 A CL 2012001950A CL 2012001950 A CL2012001950 A CL 2012001950A CL 2012001950 A1 CL2012001950 A1 CL 2012001950A1
Authority
CL
Chile
Prior art keywords
medicament
humans
animals
manufacture
bacterial strain
Prior art date
Application number
CL2012001950A
Other languages
English (en)
Inventor
Bergonzelli Gabriela
Franz Isabelle Bureau
Rodenas Clara Lucia Garcia
Original Assignee
Nestec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40785276&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012001950(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nestec Sa filed Critical Nestec Sa
Publication of CL2012001950A1 publication Critical patent/CL2012001950A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Abstract

Uso de una cepa bacteriana probiótico en la fabricación de un medicamento o composición nutricional en humanos o animales para alterar los patrones del sueño.
CL2012001950A 2008-11-03 2012-07-12 Uso de una cepa bacteriana probiotico en la fabricacion de un medicamento o composicion nutricional en humanos o animales para alterar los patrones del sueño CL2012001950A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08168161 2008-11-03

Publications (1)

Publication Number Publication Date
CL2012001950A1 true CL2012001950A1 (es) 2013-01-11

Family

ID=40785276

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2011000891A CL2011000891A1 (es) 2008-11-03 2011-04-20 Uso de la cepa probiotica lactobacillus reuteri dsm17938 o una composicion nutricional que comprende una cepa bacteriana probiotica lactobacillus reuteri dsm17938 porque sirve para preparar un medicamento o una composicion nutricional util para reducir las alteraciones de sueño y/o mejorar la calidad del sueño o los patrones de sueño en humanos o animales.
CL2012001950A CL2012001950A1 (es) 2008-11-03 2012-07-12 Uso de una cepa bacteriana probiotico en la fabricacion de un medicamento o composicion nutricional en humanos o animales para alterar los patrones del sueño

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2011000891A CL2011000891A1 (es) 2008-11-03 2011-04-20 Uso de la cepa probiotica lactobacillus reuteri dsm17938 o una composicion nutricional que comprende una cepa bacteriana probiotica lactobacillus reuteri dsm17938 porque sirve para preparar un medicamento o una composicion nutricional util para reducir las alteraciones de sueño y/o mejorar la calidad del sueño o los patrones de sueño en humanos o animales.

Country Status (16)

Country Link
US (3) US9034314B2 (es)
EP (2) EP2438821B1 (es)
CN (2) CN102960447A (es)
AU (1) AU2009319257B2 (es)
BR (1) BRPI0921617A2 (es)
CA (1) CA2742476A1 (es)
CL (2) CL2011000891A1 (es)
ES (1) ES2771176T3 (es)
MX (1) MX2011004142A (es)
MY (1) MY160376A (es)
PH (1) PH12014501749B1 (es)
PT (1) PT2438821T (es)
RU (2) RU2642301C9 (es)
TW (1) TW201029583A (es)
WO (1) WO2010060722A1 (es)
ZA (1) ZA201206546B (es)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX338680B (es) * 2009-05-11 2016-04-27 Nestec Sa Bifidobacterium longum ncc2705 (cncm i-2618) y padecimientos inmunes.
JP5923238B2 (ja) * 2010-07-07 2016-05-24 アサヒグループホールディングス株式会社 迷走神経活性化剤
EP2677886A4 (en) * 2011-02-23 2015-09-02 Biogaia Ab INDIRECT SUBSTRATES FOR MICRO-ORGANISMS FOR THE METABOLIZATION OF 1,2-PROPANDIOL
ES2677850T3 (es) 2011-06-20 2018-08-07 H.J. Heinz Company Brands Llc Composiciones y métodos probióticos
ES2572831T3 (es) * 2012-09-14 2016-06-02 Abbott Laboratories Composiciones nutricionales para su uso en métodos para modular los niveles de corticosterona en individuos con estrés psicológico
ES2795665T3 (es) 2012-09-14 2020-11-24 Abbott Lab Procedimientos para aumentar la funcionalidad cerebral utilizando 2-fucosil-lactosa
CN110651824A (zh) 2013-05-10 2020-01-07 H.J.海因茨品牌有限责任公司 益生菌和使用方法
GB201319540D0 (en) 2013-11-05 2013-12-18 Optibiotix Health Ltd Composition
GB201319531D0 (en) 2013-11-05 2013-12-18 Optibiotix Health Ltd Composition & methods of screening
GB201319539D0 (en) 2013-11-05 2013-12-18 Optibiotix Health Ltd Composition & methods of screening
GB201319538D0 (en) * 2013-11-05 2013-12-18 Optibiotix Health Ltd Composition
PL235821B1 (pl) * 2014-11-04 2020-11-02 Geo Poland Spolka Z Ograniczona Odpowiedzialnoscia Wysokoprolinowy kompleks peptydowy do zastosowania w profilaktyce i wspomaganiu leczenia zaburzeń i stanów wymagających podwyższania i/lub modulacji poziomu neurotropowego czynnika pochodzenia mózgowego jako oznaczonego w osoczu krwi biomarkera i zawierający go preparat
CN108243603A (zh) * 2015-08-31 2018-07-03 雀巢产品技术援助有限公司 使用长双歧杆菌调节情绪反应性并治疗或预防亚临床心境紊乱的方法和组合物
EP3344267A1 (en) * 2015-08-31 2018-07-11 Nestec S.A. Methods and compositions using bifidobacterium longum to treat or prevent depressive symptoms
WO2017037105A1 (en) * 2015-08-31 2017-03-09 Nestec S.A. Methods and compositions using bifidobacterium longum to optimize breastfeeding
KR101937364B1 (ko) * 2016-01-28 2019-01-11 경희대학교 산학협력단 면역조절 작용을 가는 사람 소화관 유래 신규 유산균 및 이의 용도
PL3442547T3 (pl) 2016-04-15 2023-10-23 Baylor College Of Medicine Lactobacillus reuteri mm4-1a do zastosowania w leczeniu lub profilaktyce zaburzeń ze spektrum autyzmu
SG11201809593YA (en) * 2016-07-01 2018-11-29 Nestec Sa Nutritional composition comprising a probiotic for the prevention and/or treatment of anxiety disorders and related conditions in a mammal
KR20180019474A (ko) * 2016-08-16 2018-02-26 주식회사 엠디헬스케어 락토바실러스 플란타룸 유래 소포를 포함하는 정신질환 예방 또는 치료용 조성물
AU2018263770A1 (en) * 2017-05-05 2019-10-03 Societe Des Produits Nestle S.A. Treatment of infant colic
WO2018215406A1 (en) * 2017-05-24 2018-11-29 Nestec S.A. A nutritional composition for use to enhance attention and/or reduce impulsivity
MX2019014418A (es) 2017-06-02 2020-02-24 Univ Of Otago Uso de bacterias del ácido láctico para tratar o prevenir al menos una de depresión puerperal y ansiedad puerperal.
WO2019010254A1 (en) * 2017-07-07 2019-01-10 President And Fellows Of Harvard College METHOD OF TREATING A DAMAGE INDUCED BY SLEEP
CA3072544A1 (fr) 2017-08-11 2019-02-14 Biocodex Saccharomyces boulardii pour le traitement des troubles de l'humeur
CN107712905A (zh) * 2017-11-10 2018-02-23 无比滴（广东）药业有限公司 一种液体益生菌口服液
WO2019098810A2 (ko) * 2017-11-20 2019-05-23 경희대학교 산학협력단 신규 유산균 및 이의 용도
KR102250597B1 (ko) * 2017-11-20 2021-05-11 경희대학교 산학협력단 신규 유산균 및 이의 용도
CN111886017B (zh) * 2017-12-19 2024-03-29 波比奥泰克股份公司 用于治疗和/或改善睡眠和情绪障碍的组合物
JP7303811B2 (ja) * 2017-12-19 2023-07-05 デュポン ニュートリション バイオサイエンシーズ エーピーエス 認知的及び精神的健康のためのプロバイオティクス
TWI731209B (zh) * 2018-01-09 2021-06-21 柯順議 益生菌組合物及其用途
ES2933999T3 (es) 2018-01-29 2023-02-15 Prec Group Limited Un producto combinado para la profilaxis y el tratamiento del síndrome del intestino irritable
CN111902155A (zh) * 2018-01-29 2020-11-06 精密生物集团有限公司 长双歧杆菌ncimb 41676
CN111918663A (zh) 2018-01-29 2020-11-10 精密生物集团有限公司 长双歧杆菌ncimb 41676
CN112204129B (zh) * 2018-02-02 2023-12-15 Ko生物技术有限公司 植物乳杆菌kbl396菌株及其用途
IT201800003128A1 (it) * 2018-02-28 2019-08-28 Propharma Soc A Responsabilita Limitata Semplificata Composizione probiotica
CN108186688B (zh) * 2018-03-09 2021-03-16 华大精准营养（深圳）科技有限公司 一种促进睡眠的组合物
JP7323510B2 (ja) * 2018-03-28 2023-08-08 森永乳業株式会社 睡眠促進用組成物並びに該睡眠促進用組成物を用いた医薬品組成物及び飲食品組成物
CN108823125A (zh) * 2018-06-13 2018-11-16 山东巴元生物科技有限公司 一种治疗睡眠障碍益生菌制剂的生产方法及应用
EP3701051B1 (en) 2018-07-24 2022-07-13 Biogaia AB Selection and use of melatonin supporting bacteria to reduce infantile colic
CN108949640B (zh) * 2018-08-22 2020-08-04 江南大学 短双歧杆菌ccfm1025、其发酵食品及其应用
AU2019363061A1 (en) 2018-10-17 2021-04-29 Frieslandcampina Nederland B.V. Sleep-improving compositions
CN109349645A (zh) * 2018-10-30 2019-02-19 广州普维君健药业有限公司 益生菌组合物、保健食品及其制备方法和应用
WO2020126536A1 (en) * 2018-12-21 2020-06-25 Societe Des Produits Nestle S.A. Nutritional composition for inducing a feeling of satiety, a better sleep and/or limiting nocturnal awaking in infants or young children
CN113423288A (zh) * 2019-02-04 2021-09-21 N·V·努特里奇亚 用于睡眠改善的含有不可消化的低聚糖的发酵配方物
CN111297915B (zh) * 2019-04-12 2021-11-23 首都医科大学附属北京友谊医院 治疗帕金森病快速眼动期睡眠行为障碍的益生菌组合物、制剂及用途
CN110200285A (zh) * 2019-07-23 2019-09-06 河北一然生物科技有限公司 混合益生菌那曲4580(Nagqu 4580)在改善睡眠质量的食品中的应用
CN110339218A (zh) * 2019-08-14 2019-10-18 牛占锋 一种益生菌组合物及其在改善睡眠紊乱中的应用
CA3153409A1 (en) * 2019-09-04 2021-03-11 Amare Global Nutritional supplements and methods of nutritional supplementation affecting microbiome metabolism
WO2021046459A1 (en) 2019-09-04 2021-03-11 Amare Global Nutritional supplements and methods of nutritional supplementation affecting heart/brain axis
AU2020343016A1 (en) 2019-09-04 2022-04-14 Amare Global Nutritional supplements and methods of nutritional supplementation affecting mood and focus in children
US11723941B2 (en) 2019-09-04 2023-08-15 Amare Global Nutritional supplements and methods of supplementation affecting the endocannabinoid system
JP6873291B1 (ja) * 2020-02-05 2021-05-19 雪印メグミルク株式会社 睡眠促進用組成物及び組成物を含む食品、医薬品、飼料
CN115299609A (zh) * 2022-03-21 2022-11-08 浙江臻叶茶业有限公司 一种具有改善睡眠功能的组合物及其制备方法
CN115025131B (zh) * 2022-06-02 2023-06-30 广东南芯医疗科技有限公司 罗伊氏乳杆菌e9在制备缓解焦虑、改善睡眠药物中的应用
CN115226773A (zh) * 2022-06-29 2022-10-25 湖北明慧健康科技有限责任公司 一种复合益生菌助眠固体饮料及其制备方法
CN116656549B (zh) * 2023-05-25 2023-11-14 微康益生菌(苏州)股份有限公司 一种能够改善睡眠质量的益生菌剂及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPM864894A0 (en) * 1994-10-07 1994-11-03 Borody, Thomas Julius Treatment of bowel-dependent neurological disorders
US6444203B2 (en) 1999-12-20 2002-09-03 Compagnie Gervais Danone Administering bacteria to improve sleep
AUPQ899700A0 (en) * 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
US20050100531A1 (en) * 2002-06-13 2005-05-12 John Bienenstock Probiotic therapies
JP4874532B2 (ja) 2004-08-25 2012-02-15 株式会社琉球バイオリソース開発 睡眠改善剤
JP2006160697A (ja) * 2004-12-10 2006-06-22 Kao Corp 睡眠健康改善剤
JP4344827B2 (ja) * 2005-11-28 2009-10-14 国立大学法人九州大学 スキゾキトリウム属の微生物を用いた長鎖高度不飽和脂肪酸含有リン脂質の製造方法
ES2381211T3 (es) * 2006-02-15 2012-05-24 Nestec S.A. Uso del Bifidobacterium longum para prevenir y tratar inflamaciones
US7374924B2 (en) * 2006-06-05 2008-05-20 Biogaia Ab Use of selected lactic acid bacteria for reducing infantile colic
US20070298013A1 (en) * 2006-06-23 2007-12-27 Altman Jay A Animal Nutritional Supplement and Method
JP2008137941A (ja) 2006-12-01 2008-06-19 Mitsukan Group Honsha:Kk 睡眠改善用組成物
US20080176305A1 (en) * 2006-12-20 2008-07-24 Kikkoman Corporation Functional composition
CA2679374C (en) * 2007-02-28 2016-05-31 Mead Johnson Nutrition Company Method for treating or preventing systemic inflammation
UA28995U (en) 2007-09-24 2007-12-25 Sanitary and hygienic product
EP2110028A1 (en) 2008-04-15 2009-10-21 Nestec S.A. Bifidobacterium longum and hippocampal BDNF expression

Also Published As

Publication number Publication date
US20110206649A1 (en) 2011-08-25
US20140212389A1 (en) 2014-07-31
AU2009319257B2 (en) 2014-10-09
AU2009319257A1 (en) 2010-06-03
EP2438821B1 (en) 2020-01-15
US9034314B2 (en) 2015-05-19
RU2642301C9 (ru) 2018-06-27
CL2011000891A1 (es) 2011-09-16
CA2742476A1 (en) 2010-06-03
PH12014501749A1 (en) 2016-01-18
ZA201206546B (en) 2022-03-30
EP2438821A1 (en) 2012-04-11
EP2352393A1 (en) 2011-08-10
CN102960447A (zh) 2013-03-13
CN102202527B (zh) 2014-12-31
WO2010060722A1 (en) 2010-06-03
RU2517616C2 (ru) 2014-05-27
MY160376A (en) 2017-03-15
RU2011122453A (ru) 2012-12-10
MX2011004142A (es) 2011-05-25
PT2438821T (pt) 2020-04-22
RU2642301C2 (ru) 2018-01-24
US20140242050A1 (en) 2014-08-28
CN102202527A (zh) 2011-09-28
RU2013137772A (ru) 2015-02-20
PH12014501749B1 (en) 2016-01-18
BRPI0921617A2 (pt) 2015-08-18
TW201029583A (en) 2010-08-16
ES2771176T3 (es) 2020-07-06

Similar Documents

Publication Publication Date Title
CL2012001950A1 (es) Uso de una cepa bacteriana probiotico en la fabricacion de un medicamento o composicion nutricional en humanos o animales para alterar los patrones del sueño
CO6440531A2 (es) 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso
CY1123404T1 (el) Αντι-girt αντισωματα
CL2016002589A1 (es) Uso del compuesto genz-112638 (eliglustat), inhibidor de glucosilceramida sintasa, en el tratamiento de la enfermedad de gaucher y enfermedad de fabry (divisional de solicitud 201201348).
GT200900230A (es) 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y uso
PA8772101A1 (es) Imidazol-triazolopirimidinas sustituidas
AR053803A1 (es) Uso de acido pinolenico
GT201400033A (es) Pirimidinas anilladas sustituidas y uso de las mismas
GT201400147A (es) Pirimidinas y triazinas fusionadas sustituidas y su uso
CR20110609A (es) Composicion antimicrobiana y metodos relacionados de uso
UY31228A1 (es) Ariloxazoles sustituidos y su uso
BRPI0616866A8 (pt) Enterococos probióticos para melhorar a imunidade
AR085943A1 (es) Composicion antimicrobiana
CL2012003026A1 (es) Composicion farmaceutica que comprende pioglitazona y linagliptina; procedimiento de preparacion; uso en el tratamiento de la diabetes tipo 2 o la obesidad.
UY31484A1 (es) Piperidinas heteroaril-sustituidas
EA201200550A1 (ru) Фармацевтические композиции, включающие bi-1356 и метформин
ECSP088904A (es) Arilimidazolonas y ariltriazolonas sustituidas como inhibidores de receptores de vasopresina
UY31136A1 (es) Oxazolidinonas sustituidas y su uso
EA201690147A1 (ru) Пероральные композиции
UY32052A (es) 5-aminopirazoles sustituidos y uso de los mismos
DOP2009000285A (es) (oxazolidinon-5-il-metil)-2-tiofen-carboxamidas sustituidas y su uso en el campo de la coagulacion sanguinea.
AR082215A1 (es) Composicion farmaceutica agradable al paladar
CO6700840A2 (es) Teobromina en combinación con un expectorante o un mucolítico para su uso en terapia
PA8806501A1 (es) Triazolotriazinas y triazolopirazinas y su uso
CL2013001853A1 (es) Bacteria no patogena gram negativa perteneciente a la clase betaproteobacteria y subfamilia neisseriaceae; extracto que la comprende; composicion que comprende a la bacteria o al extracto; y su uso para tratar o prevenir trastornos inflamatorios dermatologicos.